High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

References

• Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109 (Suppl II):II2–10.
   PubMedGoogle Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–43.
   PubMed Web of Science ®Google Scholar
• Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349–53.
   PubMed Web of Science ®Google Scholar
• Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein and urinary albumin levels as predictor of mortality and cardiovascular events in older adults. JAMA 2005;293:1609–16.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460–5.
   PubMed Web of Science ®Google Scholar
• Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study Group. Fragmin during instability in coronary artery disease: markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139–47.
   PubMed Web of Science ®Google Scholar
• Goetze JP, Christoffersen C, Perko, M Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105–7.
   PubMed Web of Science ®Google Scholar
• Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004;110:178–86.
   Web of Science ®Google Scholar
• Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary artery disease. N Engl J Med 2005;352:666–75.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Jablonski, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E. Prognostic significance of the centers for disease control/American Hearth Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528–36.
   PubMed Web of Science ®Google Scholar
• Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L, Gupta S, Benner RJ, Cook TD, Edwards D, Pfeffer MA. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J 2006;152:298–304.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the heart and soul study. Am J Med 2008;121:50–7.
   PubMed Web of Science ®Google Scholar
• Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Ärnlöv J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107–16.
   PubMed Web of Science ®Google Scholar
• Jespersen CM, Als-Nielsen B, Damgaard M, Hansen FF, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Gluud C. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332:22–7.
   PubMed Web of Science ®Google Scholar
• Lee-Lewandrowski E, Januzzi JL, Green SM, Tannous B, Wu AH, Smith A, Wong A, Murakami MM, Kaczmarek J, Apple FS, Miller WL, Hartman K, Jaffe AS. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay Clin Chim Acta 2007;386:20–4.
   PubMed Web of Science ®Google Scholar
• Wood WG, Lüdemann J, Mitusch R, Heinrich J, Maass R, Frick U. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and serum and the establishment of reference ranges for different groups of subjects. Clin Lab 2000;46:131–40.
   PubMedGoogle Scholar
• Allison PD. Survival analysis using SAS, a practical guide. SAS publishing, 2004.
   Google Scholar
• Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C and the CLARICOR Trial Group. High serum YKL-40 concentration in patients with stable coronary artery disease is associated with increased risk of myocardial infarction, cardiovascular death, and all-cause mortality. Eur Heart J 2009;30:1066–72.
   PubMed Web of Science ®Google Scholar
• Holm, S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65–70.
   Web of Science ®Google Scholar
• Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM, the CLARICOR Trial. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008;111:280–7.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.
   PubMed Web of Science ®Google Scholar
• O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003;290:1459–66.
   PubMed Web of Science ®Google Scholar
• Goei D, Hoeks SE, Boersma E, Winkel TA, Dunkelgrun M, Flu WJ, Schouten O, Bax JJ, Poldermans D. Incremental value of high-sensitive C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients. Coron Artery Dis 2009;20:219–24.
   PubMed Web of Science ®Google Scholar
• Li JJ, Fang CH, Qian HY, Hu WL. Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Angiology 2006;57:1–7.
   PubMed Web of Science ®Google Scholar
• Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008;30:2298–313.
   PubMed Web of Science ®Google Scholar
• Hildebrandt P, Collinson P. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 2008 Feb 4;101:25–8.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Bentley JH, , Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014–21.
   PubMed Web of Science ®Google Scholar
• Omland T. B-type natriuretic peptides: prognostic markers in stable coronary artery disease. Expert Rev Mol Diagn 2008;8:217–25.
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Niemöller K, Mehilli J, von Beckerath N, von Beckerath O, Vogt W, Schömig A, Kastrati A. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 2005:112: 2102–7.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary artery disease. JAMA 2007;297:169–76.
   PubMed Web of Science ®Google Scholar
• Richards M, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton CM, Crozier IG, Yandle TG, Doughty R, MacMahon S, Sharpe N; Christchurch Cardioendocrine Research Group; Australia-New Zealand Heart Failure Group. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Col Cardiol 2006;47: 52–60.
   PubMed Web of Science ®Google Scholar
• Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E; PEACE Investigators. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007;50:205–14.
   PubMed Web of Science ®Google Scholar
• Peer A, Falkensammer G, Alber H, Kroess A, Griesmacher A, Ulmer H, Pachinger O, Mair J. Limited utilitiesof N-terminal pro B-type natrieuretic peptide and other newer risk biomarkers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease. Heart 2009;95:297–303.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–72.
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Geeenland P, Arnett DK, Ballanryne CM, Criqui MH, Elkind MSV, Go AS, Harell FE, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConell JP, Normand SLT, O'Donell CJ, Smith SC, Wilson PWF. Criteria for evaluation of novel markers of cardiac risk. Circulation 2009;119:2408–16.
   PubMed Web of Science ®Google Scholar
• Greenland, S. The need for reorientation toward cost-effective prediction: comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M.J. Pencina et al. Stat Med 2008;27:199–206.
   PubMed Web of Science ®Google Scholar
• Hilden J, Habbema, DF. Prognosis in medicine: an analysis of its meaning and roles. Theoret Med 1987;8:349–65.
   PubMedGoogle Scholar